eplontersen to challenge Alnylam's Amvuttra AstraZeneca/Ionis's Eplontersen Shows Competitive Efficacy In ATTR Polyneuropathy At 66 Weeks. US FDA Approval
WAINUA (eplontersen) injection, for subcutaneous use This label may not be the latest approved by FDA. For current labeling information, please visit https
The recent approval of Wainua (eplontersen) by the US Food and Drug Administration (FDA) for the treatment of hereditary
In December 2024, the FDA approved eplontersen, a ligand conjugated antisense oligonucleotide, as a treatment for patients with ATTRv-PN.
The U.S. Food and Drug Administration (FDA) has granted approval to Wainua (eplontersen) for the treatment of the polyneuropathy of
FDA Approves WAINUA (Eplontersen) for Treatment of Hereditary ATTR Amyloidosis Polyneuropathy BREAKING NEWS: The U.S. Food and Drug Administration has approved AstraZeneca and Ionis WAINUA (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.
FDA Approves WAINUA (Eplontersen) for Treatment of Hereditary ATTR Amyloidosis Polyneuropathy (ATTRv-PN). 252
WAINUA (eplontersen) granted regulatory approval in the U.S. U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing
Friday, FDA approved AstraZeneca Plc (NASDAQ:AZN) and Ionis Pharmaceuticals Inc's (NASDAQ:IONS) Wainua (eplontersen) for polyneuropathy
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.
Good story - would like to see more!